Program
olomorasib
Also written as “Olomorasib”, “LY3537982” and “[¹⁴C]-LY3537982”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Renal Insufficiency · Hepatic Insufficiency, led by 3 companies.
Drug pageOlomorasib: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lillyits history only | 145 open or running | phase 3since Nov 1, 2023 | Jul 2, 2021 | Apr 2027phase 2 · NCT04956640 |
| Daiichi Sankyoits history only | 11 open or running | phase 2since Oct 16, 2026 | Oct 16, 2026 | Sep 30, 2029phase 2 · NCT07890714 |
| Johnson & Johnson | 11 open or running | phase 2since Nov 10, 2025 | Nov 10, 2025 | Nov 30, 2028phase 2 · NCT07227025 |
- Named in Eli Lilly’s own pipeline as
Olomorasib
, phase 3, as of Oct 29, 2026 (source).
Also a collaborator on its studies: AstraZeneca and Merck.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Johnson & Johnson only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Aug 11, 2024Named olomorasibINNProposed as its International Nonproprietary Name in WHO's List 131 · before, LY3537982
- Nov 10, 2025First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT07227025 · 60 planned · United States, Canada, China and more
Ahead
- Nov 30, 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07227025
TargetBeta
“An orally available inhibitor of the oncogenic KRAS substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration, olomorasib selectively targets the KRAS G12C mutant and inhibits KRAS G12C mutant-dependent signaling. KRAS, a member of the RAS family of oncogenes, …”NCIt, read by Claude
“An orally available inhibitor of the oncogenic KRAS substitution mutation, G12C, ”NCIt, by rule
Other programs on KRAS
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sotorasibrule | Amgen | phase 3 | 28 |
| adagrasibrule | Bristol-Myers Squibb | phase 3 | 16 |
| divarasib | Hoffmann-La Roche | phase 3 | 13 |
| KRAS G12D Inhibitor VS-7375rule | Genfleet Therapeutics (Shanghai) | phase 3 | 12 |
| glecirasibrule | Allist Pharmaceuticals | phase 3 | 12 |
| calderasib | Merck | phase 3 | 12 |
| daraxonrasibrule | Revolution Medicines | phase 3 | 10 |
| garsorasibrule | InventisBio | phase 3 | 8 |
| KRAS G12D Inhibitor HRS-4642 | Jiangsu HengRui Medicine | phase 3 | 7 |
| zoldonrasibrule | Revolution Medicines | phase 3 | 6 |
| HRS-7058 | Jiangsu HengRui Medicine | phase 3 | 6 |
| opnurasibrule | Novartis | phase 3 | 5 |
Studies
The one study Johnson & Johnson leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07227025Carcinoma, Non-Small-Cell Lung · United States, Canada, China and more | 2 | Recruiting | Nov 30, 2028 | 60 |
How it is read
Names in the registry
- “Olomorasib”, 8 entries
- “LY3537982”, 7 entries
- “[¹⁴C]-LY3537982”, 2 entries
- “Olomorasib test”, 1 entry
- “Olomorasib reference”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 5 studies
- Colorectal Neoplasms, 1 study
- Renal Insufficiency, 1 study
- Hepatic Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.